H.C. Wainwright initiated coverage on Nemaura Medical with a new price target
$NMRD
Medical/Dental Instruments
Health Care
H.C. Wainwright initiated coverage of Nemaura Medical with a rating of Buy and set a new price target of $12.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/29/2022 | $12.00 | Buy | H.C. Wainwright |
| 12/2/2021 | $7.50 | Buy | EF Hutton |
H.C. Wainwright initiated coverage of Nemaura Medical with a rating of Buy and set a new price target of $12.00
EF Hutton initiated coverage of Nemaura Medical with a rating of Buy and set a new price target of $7.50
4 - Nemaura Medical Inc. (0001602078) (Issuer)
3 - Nemaura Medical Inc. (0001602078) (Issuer)
4 - Nemaura Medical Inc. (0001602078) (Issuer)
WEST PALM BEACH, Fla., April 11, 2024 /PRNewswire/ -- Anthony, Linder & Cacomanolis, PLLC is proud to announce that Partner Craig D. Linder has been selected to the 2024 Top 50 Lawyers in America list for securities law. This prestigious accolade is part of the 10th annual list honoring a select group of 50 lawyers who have demonstrated outstanding leadership and success within the securities law community in the Americas. America's Top 50 Lawyers identifies and highlights the accomplishments of the nation's most distinguished and skilled attorneys in all fields of practice of law. Only 50 lawyers in each state will receive this honor and be selected for this esteemed membership. This hon
Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. ("Nemaura Medical" or the "Company"), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, is providing a crucial update regarding recent decisions that will impact Nemaura Medical's listing status on The Nasdaq Capital Market and our broader strategic direction. Background: After thorough analysis, Nemaura Medical's Board of Directors and management team have made the strategic decision to accept Nasdaq's determination to delist Nemaura Medical and move to the OTC Markets. This decision arises from a careful consideration of several factors, including challenges outside of our cont
Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ:NMRD) ("Nemaura Medical" or the "Company"), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel granted the Company's request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1st, 2024, to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market. The Company plans to continue with its commercial endeavours while pursuing its plans to ensure timely compliance with the terms of the Nasdaq Hearing Panel's decision
LOUGHBOROUGH, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the appointment of Nikolai Rozanov as strategic adviser in AI development. Mr Rozanov is a specialist in the field of artificial intelligence and was selected for inclusion by Forbes magazine in their '30 Under 30' list in the field of technology, a prestigious honour accorded to the best up-and-coming talent in the sector. The appointment of Mr Rozanov solidifies the Company's expertise in
Loughborough, England, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD)("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces the appointment of Dr. Arash (Ash) Ghadar as Chief Operating Officer. "Ash will play an important role at Nemaura as we begin to scale up our manufacturing and distribution operations. He brings over 20 years of product development, management and leadership experience spanning both business and technical disciplines. His main area of expertise is in the medical devices sector, and primarily w
Loughborough, England, April 15, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the appointment of Samantha Sanders as its Global Head of Digital Programs. Samantha has over two decades of project development, management and customer service experience, delivering successful digital projects to market within the wellbeing, pharmaceutical and medical device sector, both locally and internationally. Prior to joining the Nemaura team, more recently Samantha has bee
8-K - Nemaura Medical Inc. (0001602078) (Filer)
DEF 14C - Nemaura Medical Inc. (0001602078) (Filer)
NT 10-K - Nemaura Medical Inc. (0001602078) (Filer)
SC 13G - Nemaura Medical Inc. (0001602078) (Subject)
4 - Nemaura Medical Inc. (0001602078) (Issuer)
ORLANDO, FL / ACCESSWIRE / November 4, 2022 / RedChip Companies will air a new interview with Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, on The RedChip Money Report® on Bloomberg TV, this Saturday, November 5, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Nemaura's CEO Dr. Faz Chowdhury discusses Nemaura's continuous glucose sensor, the sugarBEAT®, its potential impact on the 500
Loughborough, England, June 30, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the fiscal year ended March 31, 2022. Corporate Highlights for FY2022: Commenced shipments of sugarBEAT® continuous glucose monitor (CGM) devices to its UK licensee, MySugarWatch Limited ("MSWL"), previously DB Ethitronix Limited. MSWL commenced mass educational and awareness campaigns to physicians in the UK via a
Loughborough, England, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the first fiscal quarter, ended June 30, 2021, of fiscal 2022. Recent Corporate Highlights: Launched a digital healthcare subscription service in the U.S. under the brand name BEAT®diabetes, targeted at over 25 million people with Type 2 diabetes and 88 million people with pre-diabetes in the U.S.Received positive feedback fro
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying The Dow Jones index closed lower by over 150 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Fortress Biotech The Trade: Fortress Biotech, Inc. (NASDAQ:FBIO) President, CEO and Chairman MD Lindsay Rosenwald acquired a total of 50,000 shares
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock increased by 113.1% to $1.3 during Thursday's after-market session. The market value of their outstanding shares is at $4.6 million. Intelligent Bio Solutions (NASDAQ:INBS) shares increased by 19.17% to $0.36. The market value of their outstanding shares is at $3.1 million. Exagen (NASDAQ:XGN) shares increased by 15.33% to $2.18. The market value of their outstanding shares is at $37.1 million. Nemaura Medical (NASDAQ:NMRD) shares increased by 12.53% to $0.12. The market value of their outstanding shares is at $3.4 million. Inspire Veterinary (NASDAQ:IVP) shares increased by 9.85% to $0.38. The market value of their outstanding shares is
Shares of Mobileye Global Inc. (NASDAQ:MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance. For the fourth quarter, the company expects revenue of $634 million-$638 million (vs. $636.39 million) and adjusted operating income of $241 million-$247 million. The company's previous implied guidance was $623 million-$648 million in revenue. Wolfe Research analyst Shreyas Patil downgraded Mobileye Global from Outperform to Peer Perform. Mobileye Global shares dipped 23.5% to $30.37 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Minim, Inc. (NASDAQ:MINM) shares jumped 170.2% t